CoChat
Sign Up
Cited by 53Antifungal resistance and susceptibilityNeutropenia and Cancer InfectionsFungal Infections and Studies

Treatment of Severe Candida Infections in High-Risk Patients in Germany: Consensus Formed by a Panel of Interdisciplinary Investigators

T., Büchner, W., Fegeler, H., Bernhardt, N., Brockmeyer, K.-H., Duswald, M., Herrmann, D., Heuser, U., Jehn +12 more·2002·European Journal of Clinical Microbiology & Infectious Diseases
DOI 10.1007/s10096-002-0730-4
Open this paper in CoChat — free account

Abstract

Now that modern medicine can provide increasing chances of cure to patients with formerly incurable disorders, therapy-related complications play the key role in outcome. Thus, among opportunistic infections, severe candidiasis remains a challenge. A multidisciplinary panel of 20 investigators was formed to find a consensus on antifungal strategies for various underlying conditions in neutropenic and non-neutropenic patients. To record their preferences, the investigators used an anonymous voting system. Among antifungal agents, fluconazole emerged as the major alternative to the classic amphotericin B, being therapeutically at least equivalent but clearly less toxic. Factors that restrict the use of fluconazole include pretreatment with azoles, involvement of resistant species like Candida krusei, and an inability to exclude aspergillosis. Flucytosine can be reasonably combined with both amphotericin B and fluconazole. Within the limited antifungal armamentarium, amphotericin B lipid formulations and itraconazole also appear useful and require further investigation. The general consensus of the group is that antifungal agents should be administered at sufficient dosages, rather early, and often empirically.

Integrity signals

Registry

Crossref · 10.1007/s10096-002-0730-4

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Amphotericin B deoxycholate has a broader spectrum than fluconazole.

    “many authorities prefer amphotericin B deoxycholate (у0.7 mg/kg per day) [126, 127] because of its broader spectrum.”

    From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [127]

  • C. glabrata often has reduced susceptibility to both azoles and amphotericin B.

    “Because C. glabrata often has reduced susceptibility to both azoles and amphotericin B, opinions on the best therapy are divided [127].”

    From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [127]

  • Fluconazole has been used successfully in clinically unstable patients infected with an unspeciated isolate.

    “For clinically unstable patients infected with an unspeciated isolate, fluconazole has been used successfully”

    From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [127]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
T., B., W., F., H., B., N., B., K.-H., D., M., H., D., H., U., J., G., J.-N., M., K., G., M., F.-M., M., J., M., J., R., N., R., M., R., A., S., R., S., G., S., & G., S.
Affiliations
  • Ludwig-Maximilians-Universität München (DE)
  • University of Würzburg (DE)
Venue
European Journal of Clinical Microbiology & Infectious Diseases
Publisher
Springer Science and Business Media LLC
Published
2002-05-01
Volume
21
Issue
5
Pages
337-352
ISSN
  • 0934-9723 (ISSN-L)
  • 1435-4373
DOI
10.1007/s10096-002-0730-4
OpenAlex
W2150108331
Cited by
53
References
78
Citations by year
2019: 1 · 2014: 1 · 2012: 3
FWCI
2.75
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • European Journal of Clinical Microbiology & Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Keywords
antifungal therapy, fluconazole, amphotericin B, 5-fluorocytosine, itraconazole, Candida krusei, aspergillosis, neutropenic patients, empirical antifungal therapy, treatment duration, antifungal resistance
MeSH terms
Antifungal Agents, Candida, Candidiasis, Chronic Disease, Colony-Stimulating Factors, Drug Administration Schedule, Germany, Humans, Lung Diseases, Fungal, Neutropenia, Risk Factors, Fungemia, Mycological Typing Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review